新络纳联合耐信治疗胃食管反流病的临床效果比较

Clinical effects of esomeprazole combined with mosapride for treatment of gastroesophageal reflux disease

目的:探讨埃索美拉唑联合莫沙必利治疗胃食管反流病(gastroesophageal reflux disease GERD)的临床效果.方法:按照随机数字表法将南阳市中心医院消化科收治的116例GERD患者均分为观察组和对照组,观察组患者给予埃索美拉唑联合莫沙必利治疗,对照组患者仅给予埃索美拉唑治疗,比较两组患者治疗前后胃食管反流病评分量表(gastroesophageal reflu disease-Q,GERD-Q)评分变化情况、幽门螺杆菌(Helicobacter pylori,H.pylori)感染率以及,临床疗效.结果:观察组和对照组患者治疗2、4、8 wk后GERD-Q评分呈现明显下降趋势,均显著低于治疗前(15.80分±2.32分vs 19.23分±2.75分、11.80分±1.88分vs 19.23分±2.75分、10.94分±1.32分v s 19.23分±2.75分,17.02分±2.06分vs 19.56分±2.55分、13.52分±1.77分v s 19.56分±2.55分、11.41分±1.46分vs 19.56分±2.55分),差异具有统计学意义(P<0.05);两组间不同时间GERD-Q评分比较(19.23分±2.75分vs 19.56分±2.55分、15.80分±2.32分vs 17.02分±2.06分、11.80分±1.88分vs 13.52分±1.77分、10.94分±1.32分v s 11.41分±1.46分),差异无统计学意义(P>0.05);观察组患者临床疗效显著优于对照组(82.76%vs 65.52%),差异具有统计学意义(P<0.05);两组患者治疗后H.pylori感染率均显著下降,与治疗前比较(17.24%vs48.28%、24.14%v s 50.00%),差异具有统计学意义(P<0.05);观察组患者治疗后H.pylori感染率低于对照组,但两组间比较(17.24%vs24.14%),差异无统计学意义(P>0.05).结论:埃索美拉唑联合莫沙必利可有效提高GERD临床疗效、改善GERD-Q评分、降低H.pylori感染率,临床疗效显著.

AIM： To explore the clinical effects of esomeprazole combined with mosapride in the treatment of gastroesophageal reflux disease. METHODS： One hundred and sixteen patients with gastroesophageal reflux disease were randomly divided into either an observation group or a control group. The observation group was treated by esomeprazole combined with mosapride, and the control group was treated by esomeprazole alone. The scores of gastroesophageal reflux disease-Q （GERD-Q）, the rate of Helicobacter pylori （H. pylori） infection and the effective rate were compared for the two groups. RESULTS： The scores of GERD-Q at 2, 4, and 8 wk post treatment were lower than that prior treatment （15.80 ± 2.32, 11.80 ± 1.88, 10.94 ± 1.32 vs 19.23 ± 2.75; 17.02 ± 2.06, 13.52 ± 1.77, 11.41 ± 1.46 vs 19.56 ± 2.55; P 〈 0.05）. There were no significant differences in the scores of GERD-Q among different time points （19.23 ± 2.75 vs 19.56 ± 2.55, 15.80 ± 2.32 vs 17.02 ± 2.06, 11.80 ± 1.88 vs 13.52 ± 1.77, 10.94 ± 1.32 vs 11.41 ± 1.46, P 〉 0.05）. The effective rate for the observation group was significantly higher than that for the control group （82.76% vs 65.52%, P 〈 0.05）. The rates of H. pylori infection post treatment for the two groups were lower than those prior treatment （17.24% vs 48.28%, 24.14% vs 50.00%, P 〈 0.05）. There was no significant difference in the rate of H. pylori infection post treatment between the two groups （17.24% vs 24.14%, P 〉 0.05）. CONCLUSION： Esomeprazole combined with mosapride has good clinical effects in the treatment of gastroesophageal reflux disease with regards to improved effective rate, scores of GERD-Q, and reduced rate of H. pylori infection.